IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer

NCT05411757 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

12

Enrollment

OTHER_GOV

Sponsor class

Conditions

Advanced Primary Liver Cancer

Interventions

COMBINATION_PRODUCT: IBR900 combined with Lenvatinib
COMBINATION_PRODUCT: IBR900 combined with Bevacizumab

Sponsor

Shandong Public Health Clinical Center

Collaborators

[object Object]